News
Trayanova Lab Publishes Precision Ablation Study in Nature Cardiovascular Research
Trayanova Lab Publishes Precision Ablation Study in Nature Cardiovascular Research The Trayanova Lab at Johns Hopkins University is excited to announce the publication of our latest research in Nature Cardiovascular Research, “Assessing the arrhythmogenic propensity of fibrotic substrate using digital twins to inform a mechanisms-based atrial fibrillation ablation strategy,” (direct Read more…
News
Trayanova Lab’s and JHMI Digital Twin Research Featured in Wall Street Journal
Trayanova Lab’s and JHMI Digital Twin Research Featured in Wall Street Journal On March 16th, the Wall Street Journal featured Dr. Trayanova and her lab’s work with JHMI on “digital twins” of people’s hearts– a method of creating a patient-specific model to study electrical problems and potentially guide therapy in a clinical environment. Read more…
News
ADVANCE researchers receive three Johns Hopkins Discovery Awards for innovative research
The three awards will enable ADVANCE researchers to develop deep learning learning methods to understand the recurrence of atrial fibrillation following catheter ablation, artificial intelligence to predict the risk of sudden death in Sarcoidosis, and computational approaches for arrhythmia risk prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Principal investigator Dr. Natalia Read more…
News
Natalia Trayanova and Eric Topol on the risk of sudden cardiac death & ICD benefit using AI
Access the PDF of their essay here or view directly in The Lancet.
News
Updates on our latest paper in Nature Cardiovascular Research
We have received a lot of publicity following Dr. Dan Popescu’s publication in Nature Cardiovascular Research. The cover of the journal’s April issue was designed by Dr. Kimberly Popescu (Dan’s wife!), featuring a schematic of a neural network embedded in cardiac tissue. Dr. Natalia Trayanova was recently interviewed by NBC Washington, Read more…
News
FDA approves our application for atrial ablation clinical trial
FDA just approved our 160-patient randomized clinical trial to demonstrate the utility of computer simulations driving atrial ablation procedure in patients with persistent atrial fibrillation and fibrosis. The approach is termed OPTIMA (OPtimal Target Identification via Modeling of Arrhythmogenesis). The PIs are Drs. Trayanova, Calkins, and Spraag — clinicians and Read more…
News
Nature Year in Review 2018: Trayanova on Precision Cardiology
ADVANCE co-director, Natalia Trayanova, PhD, discusses the key developments in precision cardiology in the December 2018 edition of Nature Reviews Cardiology. From a wearable electrocardiogram patch that may reduce the risk of stroke to a personalized virtual heart model that can direct treatment of infarct-related ventricular tachycardia, Trayanova highlights several high-impact advances Read more…